CSI Market
Sign In | Register

Checkpoint Therapeutics inc (CKPT) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access CKPT Annual Cash Flow →
Examining cash flow movements between Checkpoint Therapeutics inc and Mar 31 2024 reveals how Mar 31 2025 allocates cash as operating conditions evolve.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Mar 31 2025)
3 Months 		(Dec 31 2024) (Sep 30 2024) (Jun 30 2024) (Mar 31 2024)
Operating Activities
Income-11.21
Depreciation & amortization0.00
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation2.01
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Issuance Of Common Stock For License Expenses-
Common Shares Issuable Under Founder Agreement-
Gain Loss On Common Stock Warrant Liabilities0.06
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Other Receivables0.00
Accounts Payable-2.29
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-0.26
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-11.69
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Payment For Research And Development Licenses-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock38.12
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-6.60
Proceeds From Issuance Of Common Stock Net Of Offering Costs-
Payment Of Stock Offering Costs-
Issuance Of Common Shares At The Market Offering-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents6.60
Payment For Fractional Shares Adjustment-
Payments Of Transactional Costs For Exercise Of Warrants-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities38.12
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-11.69
Total Cash Flow26.44
4 historic quarters locked

Sign in to unlock the full Checkpoint Therapeutics inc cash flow history.

Sign In Create Free Account

About Checkpoint Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001410578-25-001233

Figures are derived from filed reports and may be restated. Historical data is subject to revision.